Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X

Blood

Volumn 106, Issue 12, 2005, Pages 3811-3815

  Sun, Yan Mei ^b   Jin, Da Yun ^b   Camire, Rodney M ^b   Stafford, Darrel W ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; EPOXIDE; HYDROQUINONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; CARBOXYLATION; CELL FRACTIONATION; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OBSERVATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 28444433035     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2495     Document Type: Article

References (26)

1. Wu SM, Cheung WF, Frazier D, Stafford DW. Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science. 1991;254:1634-1636.
2. Tie J, Wu SM, Jin D, Nicchitta CV, Stafford DW. A topological study of the human gamma-glutamyl carboxylase. Blood. 2000;96:973-978.
3. Presnell SR, Stafford DW. The vitamin K-dependent carboxylase. Thromb Haemost. 2002;87:937-946.
4. Larson AE, Friedman PA, Suttie JW. Vitamin K-dependent carboxylase: stoichiometry of carboxylation and vitamin K 2,3-epoxide formation. J Biol Chem. 1981;256:11032-11035.
5. Dowd P, Hershline R, Ham SW, Naganathan S. Vitamin K and energy transduction: a base strength amplification mechanism. Science. 1995;269:1684-1691.
6. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541-544.
7. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541.
8. Tie JK, Nicchitta C, von Heijne G, Stafford DW. Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J Biol Chem. 2005;280:16410-16416.
9. Wallin R, Martin LF. Warfarin poisoning and vitamin K antagonism in rat and human liver: design of a system in vitro that mimics the situation in vivo. Biochem J. 1987;241:389-396.
10. Shearer MJ, Barkhan P. Vitamin K1 and therapy of massive warfarin overdose. Lancet. 1979;1:266-267.
11. Preusch PC, Smalley DM. Vitamin K1 2,3-epoxide and quinone reduction: mechanism and inhibition. Free Radic Res Commun. 1990;8:401-415.
12. Wu SM, Morris DP, Stafford DW. Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci U S A. 1991;88:2236-2240.
13. Rehemtulla A, Roth DA, Wasley LC, et al. In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1993;90:4611-4615.
14. Camire RM, Larson PJ, Stafford DW, High KA. Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry. 2000;39:14322-14329.
15. Kozak M. Selection of initiation sites by eucaryotic ribosomes: effect of inserting AUG triplets upstream from the coding sequence for preproinsulin. Nucleic Acids Res. 1984;12:3873-3893.
16. Larson PJ, Camire RM, Wong D, et al. Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry. 1998;37:5029-5038.
17. Kurtz R, Batey D. Gene expression profiling from human tissues using RT-qPCR with SYBR Green 1 dye on the DNA Engine Opticon System. http://www.mjr.com/pls/portal/docs/PAGE/RESOURCE_LIBRARY/APPLICATION_NOTES/ MJRGEProf.pdf. Accessed March 10, 2005.
18. 14CO, into prothrombin. J Biol Chem. 1975;250:4744-4748.
19. Zimmerman A, Matschiner JT. Biochemical basis of hereditary resistance to warfarin in the rat. Biochem Pharmacol. 1974;23:1033-1040.
20. Wajih N, Sane DC, Hutson SM, Wallin R. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem. 2005;280:10540-10547.
21. Wajih N, Hutson SM, Owen J, Wallin R. Increased production of functional recombinant human clotting factor IX by BHK cells engineered to over express VKORC1, the vitamin K 2,3 epoxide reducing enzyme of the vitamin K cycle. J Biol Chem. 2005;280:31603-31607.
22. Hallgren KW, Hommema EL, Mcnally BA, Berkner KL. Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. Biochemistry. 2002;41:15045-15055.
23. Gardill SL, Suttie JW. Vitamin K epoxide and quinone reductase activities: evidence for reduction by a common enzyme. Biochem Pharmacol. 1990;40:1055-1061.
24. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-3864.
25. Bernard GR, Margolis BD, Shanies HM, et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest. 2004;125:2206-2216.
26. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med. 2001;29:S53-S60.